Results 271 to 280 of about 518,432 (294)
Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib
ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones +3 more
wiley +1 more source
Prognostic role of creatine kinase-MB in elderly patients with sepsis. [PDF]
Li J +6 more
europepmc +1 more source
Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia
ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of
Pannathat Soontrapa +10 more
wiley +1 more source
Structural basis for mTORC1 activation on the lysosomal membrane. [PDF]
Cui Z +4 more
europepmc +1 more source
Whole‐Body Pattern of Muscle Degeneration and Progression in Sarcoglycanopathies
ABSTRACT Objective To characterize whole‐body intramuscular fat distribution pattern in patients with sarcoglycanopathies and explore correlations with disease severity, duration and age at onset. Methods Retrospective, cross‐sectional, multicentric study enrolling patients with variants in one of the four sarcoglycan genes who underwent whole‐body ...
Laura Costa‐Comellas +39 more
wiley +1 more source
Formononetin ameliorates SP-induced urticaria in mice via suppressing TAK1/MAK signaling pathway. [PDF]
Wu Y, Li C.
europepmc +1 more source
ABSTRACT Objective Glioma recurrence severely impacts patient prognosis, with current treatments showing limited efficacy. Traditional methods struggle to analyze recurrence mechanisms due to challenges in assessing tumor heterogeneity, spatial dynamics, and gene networks.
Lei Qiu +10 more
wiley +1 more source
MAP3K1/MAP2K4 mutations drive breast cancer progression by compensating for TP53 loss through inactivation of the JNK2-p53-FOSL1 axis. [PDF]
Hu S +6 more
europepmc +1 more source
Objectives Evaluate the efficacy and safety of baricitinib in paediatric patients with active JIA‐U or chronic anterior ANA‐positive uveitis, who had an inadequate response to MTX or bDMARDs. Methods JUVE‐BRIGHT was an open‐label, active‐controlled, Phase‐3 multicentre trial which utilized a novel design, including 1:1 randomization to an active ...
Athimalaipet V. Ramanan +7 more
wiley +1 more source

